Dare Bioscience, INC

Dar Bioscience announced a $6.0 million registered direct offering of common stock and warrants, alongside a concurrent private placement of additional warrants.

Dar Bioscience, Inc. has released a corporate presentation dated July 24, 2026, intended for use in upcoming investor meetings.

Dare Bioscience has received a notice from Nasdaq indicating its common stock is subject to delisting due to non-compliance with minimum stockholders' equity requirements.

Dare Bioscience provides a corporate presentation on July 13, 2026, outlining its current initiatives and future plans.

Dar Bioscience stockholders approved the 2022 Stock Incentive Plan amendment and ratified key corporate governance proposals.

Dar Bioscience, Inc. announced the closing of its Regulation A offering, issuing 50,000 units for $5.00 each.

Dare Bioscience reported a significant net loss and increased cash burn in Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite strategic pivots and new grant funding.

Dare Bioscience, a women's health biopharmaceutical company, reported a significant net loss and cash burn in Q2 2025, raising going concern doubts, but has secured substantial post-period capital and grant funding.

Dar Bioscience reports Q1 2025 results, highlighting a net loss and going concern uncertainty, while expanding its business strategy to include Section 503B compounding.

Dare Bioscience's Q3 2024 results show a net loss, but the company's year-to-date financials are positively impacted by a significant royalty sale, while the company continues to advance its women's health product pipeline.

Dare Bioscience reports a net income of $12.9 million for the three months ended June 30, 2024, a significant turnaround from a net loss in the same period last year, primarily due to a royalty monetization transaction.

Dar Bioscience reports a net loss of $6.8 million for Q1 2024, highlighting ongoing financial challenges and the need for additional capital.

Dar Bioscience reported a significant net loss increase in 2025 and faces substantial doubt about its ability to continue as a going concern, despite advancing its product pipeline and expanding commercial strategies.

Dar Bioscience, Inc. files its 10-K report, highlighting progress in women's health innovation and strategic financial maneuvers.

Dar Bioscience enters into a royalty interest financing agreement, selling a portion of future XACIATO royalties for an initial $5 million investment and potential additional funding.

Dare Bioscience, Inc. reports that Director Gregory W. Matz was granted restricted stock units in lieu of cash compensation for board services.

Dare Bioscience, Inc. reports that Director William H. Rastetter was granted restricted stock units (RSUs) as compensation for board services.

Director William H. Rastetter was granted 10,000 stock options in Dare Bioscience, Inc. as part of standard compensation.

Director Susan L. Kelley was granted 10,000 stock options in Dare Bioscience, Inc. as part of a standard equity compensation package.

Dare Bioscience director Robin Steele was granted 10,000 stock options as part of standard equity compensation.

Director Gregory W. Matz was granted 10,000 stock options in Dare Bioscience, Inc. as part of his compensation.

Dar Bioscience, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to elect directors, ratify auditor appointment, and vote on key corporate proposals including stock issuance and equity plan amendments.

Dar Bioscience, Inc. announced the adjournment of its 2025 annual meeting of stockholders due to a lack of the required quorum, with the meeting now set to reconvene virtually on Wednesday, July 9, 2025.

DAR Bioscience, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Dar Bioscience is holding its 2025 Annual Meeting of Stockholders on June 12, 2025, to vote on director elections, auditor ratification, executive compensation, and an amendment to the 2022 Stock Incentive Plan.

DAR Bioscience, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Dar Bioscience is asking stockholders to approve a reverse stock split proposal to regain compliance with Nasdaq's minimum bid price requirement.

Dar Bioscience has filed a registration statement for the resale of up to 2.75 million shares of its common stock by Lincoln Park Capital Fund, LLC.

Law Custodial Inc. has reported a 7.8% beneficial ownership stake in Dare Bioscience, Inc., holding 1,109,428 ordinary shares.

Law Custodial Inc. has reported a 15.9% beneficial ownership stake in Dare Bioscience, Inc., holding 1,409,167 ordinary shares.